Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
The approval is good for CSL, and better for Uniqure.
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.